Everest Medicines (SEHK:1952) Is Up 15.7% After Revenue Surges And Loss Narrows In 2025 Results - Has The Bull Case Changed?

• Everest Medicines Limited recently reported full-year 2025 results, with sales of CNY 1,706.68 million versus CNY 706.68 million a year earlier and a net loss of CNY 297.77 million compared with CNY 1,041.38 million, alongside presentations at the American College of Cardiology 75th Annual Scientific Session in New Orleans in March 2026.
• The sharp increase in revenue and much smaller loss per share point to materially improved operating efficiency that could reshape how investors view the company’s path toward profitability.
• We’ll now examine how this sharp revenue growth and narrower loss profile may influence Everest Medicines’ investment narrative and future expectations.

Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Everest Medicines Investment Narrative Recap

To own Everest Medicines, you need to believe its growing renal and autoimmune portfolio can eventually support sustainable profits despite ongoing losses and execution risks. The latest 2025 results, with sharply higher revenue and a smaller net loss, strengthen the near term catalyst of scaling NEFECON and preparing the VELSIPITY roll out, while the biggest risk remains heavy dependence on a few key products in a volatile pricing and reimbursement setting.

The full year 2025 earnings release is the clearest linked catalyst here, as it shows sales rising to CNY 1,706.68 million and net loss narrowing to CNY 297.77 million. This progress ties directly to the consensus thesis that broader access for NEFECON and future VELSIPITY contributions could improve operating leverage, even as investors continue to weigh concentration risk and the cost of funding Everest’s broader pipeline.

Yet behind the revenue jump, there is still the underappreciated risk that tighter reimbursement or competing therapies could quickly change what investors should be aware of...

Read the full narrative on Everest Medicines (it's free!)

Everest Medicines’ narrative projects CN¥3.7 billion revenue and CN¥978.7 million earnings by 2029.

Uncover how Everest Medicines' forecasts yield a HK$56.76 fair value, a 49% upside to its current price.

Exploring Other Perspectives

Before this earnings jump, the most optimistic analysts were assuming Everest could reach about CNY 4.9 billion in revenue and CNY 1.2 billion in earnings by 2028, so compared with the baseline focus on gradual improvement and product concentration risk, that is a far more upbeat story that you should weigh against the possibility that reliance on NEFECON and VELSIPITY in China might be a bigger swing factor than those forecasts suggest.

Explore another fair value estimate on Everest Medicines - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Everest Medicines research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Everest Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Everest Medicines' overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com